Who is sponsoring NCT02937948?

NCT02937948 is sponsored by Center Eugene Marquis.

What drugs are being tested in NCT02937948?

Interventions in NCT02937948: Adaptative treatment plan, External radiotherapy.

What condition does NCT02937948 study?

NCT02937948 studies Uterine Cervical Cancer.

Is NCT02937948 still recruiting?

NCT02937948 is currently completed. Last updated 2 September 2022.

Last reviewed 2022-09-02 · How we verify

NCT02937948: ARCOL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adaptative Radiotherapy for Locally Advanced Cervical Cancer

Completed NA Last updated 2 September 2022

What this trial tests

NA trial testing Adaptative treatment plan in Uterine Cervical Cancer in 85 participants. Completed in 11 April 2022.

Timeline

5 April 2017

Primary endpoint
27 May 2020

11 April 2022

Quick facts

Lead sponsor	Center Eugene Marquis
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	85
Start date	5 April 2017
Primary completion	27 May 2020
Estimated completion	11 April 2022
Sites	12 locations across France

Drugs / interventions tested

Adaptative treatment plan
External radiotherapy

Conditions studied

Uterine Cervical Cancer — all drugs for Uterine Cervical Cancer →

Sponsor

Center Eugene Marquis — full company profile →

Who can join

18 and older, female only, with Uterine Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effect of adaptative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of locally advanced cervical cancer on acute genito-urinary (GU), and gastrointestinal (GI) toxicities. Every patients will be treated according to the adaptative IMRT strategy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Uterine Cervical Cancer

Currently open trials in the same condition.

NCT04516616 — Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer · Phase 2 · active not recruiting
NCT04857528 — Detecting HPV DNA in Anal and Cervical Cancers · recruiting

Other Center Eugene Marquis trials

Trials by the same sponsor.

NCT07189598 — Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer · NA · recruiting
NCT07122089 — Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis · Phase 2 · not yet recruiting
NCT06551272 — Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma · Phase 2 · recruiting
NCT06627075 — Optical Surface Guidance for External Radiotherapy of Head and Neck Cancer · NA · recruiting
NCT06583460 — Systematic Intervention to Improve Sexual Dysfunction · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02937948 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center Eugene Marquis
Last refreshed: 2 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02937948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing